177 related articles for article (PubMed ID: 37967656)
21. Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models.
Feng B; Doran AC; Di L; West MA; Osgood SM; Mancuso JY; Shaffer CL; Tremaine L; Liras J
J Pharm Sci; 2018 Aug; 107(8):2225-2235. PubMed ID: 29608887
[TBL] [Abstract][Full Text] [Related]
22. Quantitative insight into the design of compounds recognized by the L-type amino acid transporter 1 (LAT1).
Ylikangas H; Malmioja K; Peura L; Gynther M; Nwachukwu EO; Leppänen J; Laine K; Rautio J; Lahtela-Kakkonen M; Huttunen KM; Poso A
ChemMedChem; 2014 Dec; 9(12):2699-707. PubMed ID: 25205473
[TBL] [Abstract][Full Text] [Related]
23. Structural Features Affecting the Interactions and Transportability of LAT1-Targeted Phenylalanine Drug Conjugates.
Bahrami K; Järvinen J; Laitinen T; Reinisalo M; Honkakoski P; Poso A; Huttunen KM; Rautio J
Mol Pharm; 2023 Jan; 20(1):206-218. PubMed ID: 36394563
[TBL] [Abstract][Full Text] [Related]
24. L-Type Amino Acid Transporter 1 (LAT1/Lat1)-Utilizing Prodrugs Can Improve the Delivery of Drugs into Neurons, Astrocytes and Microglia.
Huttunen J; Peltokangas S; Gynther M; Natunen T; Hiltunen M; Auriola S; Ruponen M; Vellonen KS; Huttunen KM
Sci Rep; 2019 Sep; 9(1):12860. PubMed ID: 31492955
[TBL] [Abstract][Full Text] [Related]
25. Practical Application of Rodent Transporter Knockout Models to Assess Brain Penetration in Drug Discovery.
Eneberg E; Jones CR; Jensen T; Langthaler K; Bundgaard C
Drug Metab Bioanal Lett; 2022; 15(1):12-21. PubMed ID: 35196975
[TBL] [Abstract][Full Text] [Related]
26. Amino Acid Promoieties Alter Valproic Acid Pharmacokinetics and Enable Extended Brain Exposure.
Gynther M; Peura L; Vernerová M; Leppänen J; Kärkkäinen J; Lehtonen M; Rautio J; Huttunen KM
Neurochem Res; 2016 Oct; 41(10):2797-2809. PubMed ID: 27412117
[TBL] [Abstract][Full Text] [Related]
27. Validation of Human MDR1-MDCK and BCRP-MDCK Cell Lines to Improve the Prediction of Brain Penetration.
Feng B; West M; Patel NC; Wager T; Hou X; Johnson J; Tremaine L; Liras J
J Pharm Sci; 2019 Jul; 108(7):2476-2483. PubMed ID: 30794795
[TBL] [Abstract][Full Text] [Related]
28. Brain Distribution of a Panel of Epidermal Growth Factor Receptor Inhibitors Using Cassette Dosing in Wild-Type and
Kim M; Laramy JK; Mohammad AS; Talele S; Fisher J; Sarkaria JN; Elmquist WF
Drug Metab Dispos; 2019 Apr; 47(4):393-404. PubMed ID: 30705084
[TBL] [Abstract][Full Text] [Related]
29. Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma.
Becker CM; Oberoi RK; McFarren SJ; Muldoon DM; Pafundi DH; Pokorny JL; Brinkmann DH; Ohlfest JR; Sarkaria JN; Largaespada DA; Elmquist WF
Neuro Oncol; 2015 Sep; 17(9):1210-9. PubMed ID: 25972455
[TBL] [Abstract][Full Text] [Related]
30. Organic Cation Transporters are Involved in Fluoxetine Transport Across the Blood-Brain Barrier
Wang M; Sun Y; Hu B; He Z; Chen S; Qi D; An H; Wei Y
Curr Drug Deliv; 2022; 19(4):508-517. PubMed ID: 34238184
[TBL] [Abstract][Full Text] [Related]
31. Recent advances in the in vitro and in vivo methods to assess impact of P-glycoprotein and breast cancer resistance protein transporters in central nervous system drug disposition.
Chatterjee S; Deshpande AA; Shen H
Biopharm Drug Dispos; 2023 Feb; 44(1):7-25. PubMed ID: 36692150
[TBL] [Abstract][Full Text] [Related]
32. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.
Agarwal S; Sane R; Gallardo JL; Ohlfest JR; Elmquist WF
J Pharmacol Exp Ther; 2010 Jul; 334(1):147-55. PubMed ID: 20421331
[TBL] [Abstract][Full Text] [Related]
33. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
[TBL] [Abstract][Full Text] [Related]
34. Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier.
Poller B; Drewe J; Krähenbühl S; Huwyler J; Gutmann H
Cell Mol Neurobiol; 2010 Jan; 30(1):63-70. PubMed ID: 19629677
[TBL] [Abstract][Full Text] [Related]
35. Glucose promoiety enables glucose transporter mediated brain uptake of ketoprofen and indomethacin prodrugs in rats.
Gynther M; Ropponen J; Laine K; Leppänen J; Haapakoski P; Peura L; Järvinen T; Rautio J
J Med Chem; 2009 May; 52(10):3348-53. PubMed ID: 19402664
[TBL] [Abstract][Full Text] [Related]
36. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.
Minocha M; Khurana V; Qin B; Pal D; Mitra AK
Int J Pharm; 2012 Sep; 434(1-2):306-14. PubMed ID: 22633931
[TBL] [Abstract][Full Text] [Related]
37. Regulation of P-glycoprotein and Breast Cancer Resistance Protein Expression Induced by Focused Ultrasound-Mediated Blood-Brain Barrier Disruption: A Pilot Study.
Conti A; Geffroy F; Kamimura HAS; Novell A; Tournier N; Mériaux S; Larrat B
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555129
[TBL] [Abstract][Full Text] [Related]
38. Acyclovir Brain Disposition: Interactions with P-gp, Bcrp, Mrp2, and Oat3 at the Blood-Brain Barrier.
Shan Y; Cen Y; Zhang Y; Tan R; Zhao J; Nie Z; Zhang J; Yu S
Eur J Drug Metab Pharmacokinet; 2022 Mar; 47(2):279-289. PubMed ID: 35112329
[TBL] [Abstract][Full Text] [Related]
39. Drug Delivery Strategies to Overcome the Blood-Brain Barrier (BBB).
Helms HCC; Kristensen M; Saaby L; Fricker G; Brodin B
Handb Exp Pharmacol; 2022; 273():151-183. PubMed ID: 33367937
[TBL] [Abstract][Full Text] [Related]
40. Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban.
Jacqueroux E; Hodin S; Saib S; He Z; Bin V; Delézay O; Delavenne X
Eur J Pharm Biopharm; 2020 Mar; 148():27-37. PubMed ID: 31945490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]